Grant: Collaborative Health Research Projects
University of Western Ontario
$91,599.00
CCN3: a novel antifibrotic treatment?
EF 2016-17
Résumé
Fibrotic diseases such as scleroderma have no therapy. These diseases are characterized by extensive scar tissuedeposition. The cells (fibroblasts) within the scar are subject to enhanced tension due to the surrounding scar tissue. Theyalso themselves are abnormal in that they exert excessive tension on the scar tissue. It is believed that this excessivetension is responsible for the maintenance of the scar. A protein called CCN2 is expressed specifically in scar tissue andpromotes this tension. A related protein CCN3 is not found in scar tissue, but normally acts to inhibit CCN2. We want to testwhether CCN3 (and peptides derived from CCN3) can block scleroderma fibrosis. Moreover, we want to test if monitoringthe CCN2:CCN3 ratio in patients can be used to monitor disease progression At the end of the funding period, we will designandinitiate clinical trials with our peptides to see if we can block fibrosis clinically.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
493636-2016
Name nom
Leask, Andrew
Department département
Dentistry, School of
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
91599
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
CCN3: a novel antifibrotic treatment?
Keyword
NSERC
Application summary
Fibrotic diseases such as scleroderma have no therapy. These diseases are characterized by extensive scar tissuedeposition. The cells (fibroblasts) within the scar are subject to enhanced tension due to the surrounding scar tissue. Theyalso themselves are abnormal in that they exert excessive tension on the scar tissue. It is believed that this excessivetension is responsible for the maintenance of the scar. A protein called CCN2 is expressed specifically in scar tissue andpromotes this tension. A related protein CCN3 is not found in scar tissue, but normally acts to inhibit CCN2. We want to testwhether CCN3 (and peptides derived from CCN3) can block scleroderma fibrosis. Moreover, we want to test if monitoringthe CCN2:CCN3 ratio in patients can be used to monitor disease progression At the end of the funding period, we will designandinitiate clinical trials with our peptides to see if we can block fibrosis clinically.
